175 related articles for article (PubMed ID: 32862501)
1. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
Cancer Med; 2020 Oct; 9(20):7548-7557. PubMed ID: 32862501
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
3. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
Breast Cancer Res Treat; 2021 Jan; 185(2):507-515. PubMed ID: 33064230
[TBL] [Abstract][Full Text] [Related]
4. A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.
Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
Breast Cancer Res Treat; 2021 Feb; 185(3):807-815. PubMed ID: 33090268
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer.
Haiderali A; Rhodes WC; Gautam S; Huang M; Sieluk J; Skinner KE; Schwartzberg LS
Future Oncol; 2021 Oct; 17(29):3833-3841. PubMed ID: 34254533
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan.
Sanno H; Taniguchi K; Yoshimoto Y; Saji S
Future Oncol; 2024 Apr; 20(13):833-849. PubMed ID: 38305038
[TBL] [Abstract][Full Text] [Related]
7. Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010-2016.
Sieluk J; Haiderali A; Huang M; Yang L; Hirshfield KM
Future Oncol; 2021 Mar; 17(9):1039-1054. PubMed ID: 33261515
[No Abstract] [Full Text] [Related]
8. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
[TBL] [Abstract][Full Text] [Related]
9. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
Aly A; Shah R; Hill K; Botteman MF
Future Oncol; 2019 Mar; 15(9):1007-1020. PubMed ID: 30717602
[TBL] [Abstract][Full Text] [Related]
10. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.
Hsu JY; Chang CJ; Cheng JS
Sci Rep; 2022 Jan; 12(1):729. PubMed ID: 35031634
[TBL] [Abstract][Full Text] [Related]
11. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
[TBL] [Abstract][Full Text] [Related]
12. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.
Huang M; Haiderali A; Fox GE; Frederickson A; Cortes J; Fasching PA; O'Shaughnessy J
Pharmacoeconomics; 2022 May; 40(5):519-558. PubMed ID: 35112331
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns Among Women Diagnosed With Stage I-III Triple-negative Breast Cancer.
Sineshaw HM; Freedman RA; DeSantis CE; Jemal A
Am J Clin Oncol; 2018 Oct; 41(10):997-1007. PubMed ID: 29278527
[TBL] [Abstract][Full Text] [Related]
14. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
16. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
17. Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study.
Rapiti E; Pinaud K; Chappuis PO; Viassolo V; Ayme A; Neyroud-Caspar I; Usel M; Bouchardy C
Cancer Med; 2017 Mar; 6(3):526-536. PubMed ID: 28211614
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
[No Abstract] [Full Text] [Related]
19. Characteristics of male triple negative breast cancer: A population-based study.
Ghani S; Sochat M; Luo J; Tao Y; Ademuyiwa F
Breast J; 2020 Sep; 26(9):1748-1755. PubMed ID: 32856383
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
